Market Place
Sourcing Support
Curevac Reveals Q3 & 9-Month 2025 Financials, Business Updates
24 Nov 2025 //
PHARMIWEB
CureVac Named Among World’s Top Innovators By LexisNexis
18 Feb 2025 //
ACCESSWIRE
CureVac to Present at SITC 39th Annual Meeting
28 Oct 2024 //
ACCESSWIRE
CureVac Updates On Patent Litigation Trial Dates Against Pfizer/BioNTech
11 Jul 2024 //
ACCESSWIRE
Agomab Appoints Pierre Kemula As Chief Financial Officer
11 Jul 2024 //
BUSINESSWIRE
CureVac Announces Voting Results Of General Meeting
24 Jun 2024 //
ACCESSWIRE
CureVac Announces Financial Results for the Third Quarter
14 Nov 2023 //
ACCESSWIRE
CureVac Announces Update to the Management Team
14 Jul 2023 //
ACCESSWIRE
CureVac Announces Financial Results for the 4Q Full-Year 2022
25 Apr 2023 //
ACCESSWIRE
CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results
18 Apr 2023 //
ACCESSWIRE
CureVac Members of Management Sell Shares to Cover Tax Obligations
14 Dec 2022 //
ACCESSWIRE
CureVac rethinks lead cancer program after posting PD-1 data
17 Nov 2022 //
FIERCEBIOTECH
CureVac Announces Financial Results for the Third Quarter
16 Nov 2022 //
ACCESSWIRE
CureVac Presents Preliminary Data from Phase 1 Study Expansion Oncology CV8102
11 Nov 2022 //
ACCESSWIRE
Pfizer, BioNTech seek to revoke CureVac`s patent infringement claims
02 Sep 2022 //
REUTERS
CureVac Starts PI Study of Modified, Omicron-Targeting COVID-19 Vaccine
18 Aug 2022 //
ACCESSWIRE
CureVac Announces Financial Results for Q2 and H1 of 2022
18 Aug 2022 //
ACCESSWIRE
CureVac, GSK load into starting block in omicron booster race
18 Aug 2022 //
FIERCEBIOTECH
Pfizer and BioNTech contest CureVac COVID shot patent charges
27 Jul 2022 //
FIERCEPHARMA
BioNTech could owe CureVac $500M in royalties if suit succeeds
12 Jul 2022 //
FIERCEPHARMA
CureVac files patent lawsuit in Germany against BioNTech over mRNA tech
06 Jul 2022 //
BUSINESS-STANDARD
CureVac inks biotech buyout to step up cancer vaccine R&D
10 Jun 2022 //
FIERCEBIOTECH
CureVac Announces Changes of CDO - Myriam Mendila to Succeed Klaus Edvardsen
08 Jun 2022 //
ACCESSWIRE
CureVac Accelerates Oncology Strategy; Acquires Frame Cancer Therapeutics
08 Jun 2022 //
ACCESSWIRE
CureVac tries to turn the page to next-gen mRNA tech
26 May 2022 //
FIERCEBIOTECH
CureVac Partners with myNEO for New Antigen Target for mRNA-Based Cancer Vaccine
25 May 2022 //
CUREVAC
CureVac Announces Financial Results for Q4 and Full-Year 2021
28 Apr 2022 //
ACCESSWIRE
CureVac and GSK`s Bivalent Second-Generation mRNA Vaccine Candidate Shown
21 Apr 2022 //
ACCESSWIRE
CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results
21 Apr 2022 //
ACCESSWIRE
Germany agrees deal with CureVac, GSK for mRNA vaccines until 2029
12 Apr 2022 //
REUTERS
CureVac, GSK Initiate Next-Gen COVID Vax Trial
31 Mar 2022 //
CONTRACTPHARMA
CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry
17 Jan 2022 //
PRESS RELEASE
AZ, Moderna shine early light on mRNA potential in heart failure
16 Nov 2021 //
FIERCEBIOTECH
CureVac Presents Promising Data at SITC from Ph1 Study of OncologyCV8102
10 Nov 2021 //
CUREVAC
CureVac Withdraws COVID-19 Vaccine Application in EU
20 Oct 2021 //
FDANEWS
CureVac to focus on second-generation mRNA vaccine candidates
13 Oct 2021 //
PHARMACEUTICAL-TECHNOLOGY
CureVac giving up on first COVID mRNA vaccine
13 Oct 2021 //
NYTIMES
EMA ends rolling review of CVnCoV vaccine post withdrawal by CureVac AG
12 Oct 2021 //
EMA
CureVac scraps its first COVID-19 vaccine and pivots to a second
12 Oct 2021 //
BIOPHARMADIVE
EMA Sees Decision on CureVac Covid Shot Unlikely Before Year-End
24 Sep 2021 //
BLOOMBERGLAW
CureVac slashes COVID-19 vaccine production plans
15 Sep 2021 //
REUTERS
CureVac`s CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet
31 Aug 2021 //
PRESS RELEASE
CureVac Demonstrated Positive Preclinical Data
30 Aug 2021 //
PRESS RELEASE
COVID-19 vaccine tracker
23 Aug 2021 //
RAPS
GSK/CureVac’s mRNA Covid-19 vaccine boosts immune response in preclinical study
17 Aug 2021 //
PHARMACEUTICALTECHNOLOGY
CureVac to push ahead with first- and second-generation COVID-19 vaccines
17 Aug 2021 //
PM LIVE
CureVac to push ahead with first- and second-generation COVID-19 vaccines
17 Aug 2021 //
PM LIVE
Boehringer Ingelheim scraps $600M+ lung cancer program with CureVac
17 Aug 2021 //
FIERCEBIOTECH
GSK and CureVac’s second vaccine yields stronger response.
16 Aug 2021 //
REUTERS
Boehringer Ingelheim scraps $600M+ lung cancer program with CureVac.
16 Aug 2021 //
ENDPTS
GSK, CureVac`s next-gen COVID-19 vaccine shows promise in monkey trial
16 Aug 2021 //
REUTERS
The 7-year itch? Boehringer culls $600M cancer pact with CureVac, heaping more woe to the biotech
16 Aug 2021 //
FIERCE BIOTECH
In CureVac`s failure, a possible verdict on the past (and future) of mRNA Jab
29 Jul 2021 //
ENDPTS
In CureVac`s failure, a possible verdict on the past (and future) of mRNA vaccines
29 Jul 2021 //
ENDPTS
‘The race is on’: CureVac seeks answers to vaccine disappointment
21 Jul 2021 //
FINANCIAL TIMES
Novartis set to deliver 50 million CureVac COVID-19 vaccines this year
21 Jul 2021 //
REUTERS
CureVac gains COO and hands Florian von der Mülbe new assignment
02 Jul 2021 //
ENDPTS
CureVac vows to seek vaccine approval despite low efficacy in COVID-19 study
02 Jul 2021 //
BIOPHARMADIVE
CureVac says speaking to EU about ideal region to use vaccine
02 Jul 2021 //
REUTERS
CureVac looks to subgroup to save failed COVID-19 vaccine
02 Jul 2021 //
FIERCEBIOTECH
